CANCER:

Thymus Cancer

Related cancers:

‹

Thymic Carcinoma (30)

Thymoma (21)

Thymic Carcinoma (30)

Thymoma (21)

›

No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	lenvatinib Sensitive: A1 - Approval
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	GEM-CAP Sensitive: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	LV5FU2 Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	GEM-CAP Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	LV5FU2 Sensitive: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	CaT Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	CaT Sensitive: A2 - Guideline
KIT mutation KIT mutation	Thymic Carcinoma Thymic Carcinoma	sunitinib Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	VIP Sensitive: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	VIP Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	CAP Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	ifosfamide Sensitive: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	EP Sensitive: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	ADOC Sensitive: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	CAP + prednisone Sensitive: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	CAP Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	CAP + prednisone Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	ADOC Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	EP Sensitive: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	carboplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	carboplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	pembrolizumab Resistant: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	ifosfamide Sensitive: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	etoposide oral Sensitive: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	prednisone + octreotide Sensitive: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	octreotide Sensitive: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	everolimus Sensitive: A2 - Guideline
No biomarker No biomarker	Thymic Carcinoma Thymic Carcinoma	pemetrexed Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	pemetrexed Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	prednisone + octreotide Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	octreotide Sensitive: A2 - Guideline
No biomarker No biomarker	Thymoma Thymoma	everolimus Sensitive: A2 - Guideline
EIF4EBP1 expression EIF4EBP1 expression	Thymic Carcinoma Thymic Carcinoma	everolimus Resistant: C3 – Early Trials
HER-2 positive HER-2 positive	Thymic Carcinoma Thymic Carcinoma	pyrotinib Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Thymic Carcinoma Thymic Carcinoma	pyrotinib Sensitive: C3 – Early Trials
IGF1R expression IGF1R expression	Thymoma Thymoma	everolimus Resistant: C3 – Early Trials
IGF1R expression IGF1R expression	Thymic Carcinoma Thymic Carcinoma	everolimus Resistant: C3 – Early Trials
EIF4EBP1 expression EIF4EBP1 expression	Thymoma Thymoma	everolimus Resistant: C3 – Early Trials
KIT D820Y KIT D820Y	Thymic Carcinoma Thymic Carcinoma	sorafenib Sensitive: C4 – Case Studies
PD-L1 overexpression PD-L1 overexpression	Thymic Carcinoma Thymic Carcinoma	pembrolizumab Sensitive: C4 – Case Studies
PD-L1 overexpression PD-L1 overexpression	Thymic Carcinoma Thymic Carcinoma	pembrolizumab Resistant: C4 – Case Studies
PD-L1 overexpression PD-L1 overexpression	Thymoma Thymoma	pembrolizumab Sensitive: C4 – Case Studies
EGFR exon 20 insertion EGFR exon 20 insertion	Thymic Carcinoma Thymic Carcinoma	anlotinib Sensitive: C4 – Case Studies
EGFR exon 19 deletion EGFR exon 19 deletion	Thymic Carcinoma Thymic Carcinoma	icotinib Sensitive: C4 – Case Studies
MSLN expression MSLN expression	Thymic Carcinoma Thymic Carcinoma	BAY 94-9343 Sensitive: D – Preclinical

Thymus Cancer

Associations(51)

Associations
(51)